ClinicalTrials.gg

Program

AZD6793

A development code.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Diabetes Mellitus, Type 2, led by AstraZeneca.

Furthest: phase 2, since Jun 11, 20255 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca51 open or runningphase 2since Jun 11, 2025Nov 16, 2022Aug 31, 2027phase 2 · NCT07082738
  • Named in AstraZeneca’s own pipeline as AZD6793, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2022First study: phase 1 study in Inflammatory DiseasesFirst studyNCT05662033 · 93 enrolled · United Kingdom
  2. Apr 11, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06368440 · 39 enrolled · United States
  3. Jul 3, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06494644 · 17 enrolled · Germany
  4. Jun 11, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07082738 · 987 planned · United States, Argentina, Australia and more
  5. Dec 23, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07433062 · 28 enrolled · Germany

Ahead

  1. Aug 31, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07082738

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07433062Diabetes Mellitus, Type 2 · Germany1SuspendedJun 18, 202628
NCT07082738Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more2RecruitingAug 31, 2027987
NCT06494644Pulmonary Disease, Chronic Obstructive · Germany1CompletedOct 5, 202417
NCT06368440Pulmonary Disease, Chronic Obstructive · United States1CompletedDec 23, 202439
NCT05662033Inflammatory Diseases · United Kingdom1CompletedOct 29, 202493

How it is read

Names in the registry

  • “AZD6793”, 6 entries

Codes read as this program: AZD6793.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.